Cargando…

1395. Defining the Magnitude of AUC:MIC Driver for Efficacy of the β-Lactamase Inhibitor VNRX-5133 When Combined with Cefepime Against KPC- and VIM/NDM-Producing Enterobacteriaceae and P. aeruginosa

BACKGROUND: VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) in clinical development with cefepime for treatment of infections caused by ESBL- and carbapenemase producing Enterobacteriaceae and P. aeruginosa. It is a new generation broad-spectrum BLI with direct inhibitory activity against...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daigle, Denis, Vernacchio, Salvador, Xerri, Luigi, Pevear, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252669/ http://dx.doi.org/10.1093/ofid/ofy210.1226

Ejemplares similares

1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa
por: Daigle, Denis, et al.
Publicado: (2018)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes
por: Hackel, Meredith, et al.
Publicado: (2018)

1310. Implementation of AUC:MIC Pharmacy to Dose in an Academic Medical Center: A Pilot Study
por: Idusuyi, Ann-Marie, et al.
Publicado: (2020)

2193. Vancomycin AUC:MIC Monitoring: Transitioning Safely from Inpatient to Outpatient Monitoring via OPAT
por: Campion, Maureen, et al.
Publicado: (2023)

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
por: Liu, Bin, et al.
Publicado: (2019)

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
por: Krajnc, Alen, et al.
Publicado: (2019)

203. Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
por: Hackel, Meredith, et al.
Publicado: (2021)

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor
por: Dowell, James A., et al.
Publicado: (2021)

1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model
por: Abdelraouf, Kamilia, et al.
Publicado: (2018)

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
por: Trout, Robert E., et al.
Publicado: (2021)

1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
por: Avery, Lindsay M, et al.
Publicado: (2020)

1401. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects
por: Geibel, Brooke, et al.
Publicado: (2018)

A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae
por: Boutal, Hervé, et al.
Publicado: (2018)

Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China
por: Han, Renru, et al.
Publicado: (2020)

Detection of KPC, NDM and VIM-Producing Organisms Directly from Rectal Swabs by a Multiplex Lateral Flow Immunoassay
por: Vasilakopoulou, Alexandra, et al.
Publicado: (2021)

Multi-centre evaluation of real-time multiplex PCR for detection of carbapenemase genes OXA-48, VIM, IMP, NDM and KPC
por: van der Zee, Anneke, et al.
Publicado: (2014)

835. Comparison of the outcomes of patients with KPC and NDM-1-producing Enterobacteriaceae
por: Seo, Hyeonji, et al.
Publicado: (2020)

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli
por: Roach, Elyse J., et al.
Publicado: (2021)

Rapid Identification of OXA-48-like, KPC, NDM, and VIM Carbapenemase-Producing Enterobacteriaceae From Culture: Evaluation of the RESIST-4 O.K.N.V. Multiplex Lateral Flow Assay
por: Song, Wonkeun, et al.
Publicado: (2020)

Evaluation of a modified meropenem hydrolysis assay on a large cohort of KPC and VIM carbapenemase-producing Enterobacteriaceae
por: Calderaro, Adriana, et al.
Publicado: (2017)

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
por: Chatwin, Cassandra L., et al.
Publicado: (2021)

1220. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant E. coli and Klebsiella spp
por: Heil, Emily, et al.
Publicado: (2021)

KPC and NDM-1 Genes in Related Enterobacteriaceae Strains and Plasmids from Pakistan and the United States
por: Pesesky, Mitchell W., et al.
Publicado: (2015)

Unusual association of NDM-1 with KPC-2 and armA among Brazilian Enterobacteriaceae isolates
por: Quiles, M.G., et al.
Publicado: (2014)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
por: Su, Ting-Yi, et al.
Publicado: (2017)

Therapeutic drug monitoring of vancomycin by AUC(τ)-MIC ratio in patients with chronic kidney disease
por: Khoei, Ahmad, et al.
Publicado: (2019)

Evaluation of traditional initial vancomycin dosing versus utilizing an electronic AUC/MIC dosing program
por: Mcgrady, Kerri A., et al.
Publicado: (2020)

AMA overcomes antibiotic resistance by NDM and VIM metallo-β-lactamases
por: King, Andrew M., et al.
Publicado: (2014)

Genotypic to Phenotypic Resistance Discrepancies Identified Involving β-Lactamase Genes, blaKPC, blaIMP, blaNDM-1, and blaVIM in Uropathogenic Klebsiella pneumoniae
por: Urmi, Umme Laila, et al.
Publicado: (2020)

Comparison of Four Commercial Screening Assays for the Detection of bla(KPC), bla(NDM), bla(IMP), bla(VIM,) and bla(OXA48) in Rectal Secretion Collected by Swabs
por: Del Bianco, Francesca, et al.
Publicado: (2019)

Evaluation of the SpeeDx Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes
por: Bordin, Amanda, et al.
Publicado: (2019)

Evaluation of the RESIST-4 O.K.N.V immunochromatographic lateral flow assay for the rapid detection of OXA-48, KPC, NDM and VIM carbapenemases from cultured isolates
por: MacDonald, James Wesley, et al.
Publicado: (2019)

Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus
por: Eum, Seenae, et al.
Publicado: (2016)

α-Aminophosphonate inhibitors of metallo-β-lactamases NDM-1 and VIM-2
por: Palica, Katarzyna, et al.
Publicado: (2023)

Pseudomonas aeruginosa Coharboring Bla(KPC-2) and Bla(VIM-2) Carbapenemase Genes
por: Pacheco, Tatiana, et al.
Publicado: (2019)

Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing Enterobacteriaceae Isolated from the Mohamed VI University Hospital in Marrakech, Morocco
por: Loqman, Souad, et al.
Publicado: (2021)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i3sm3ah6df9ti6i3m2b8go1cv1